Breast cancer treatment combination and dose improves survival in people with inherited BRCA1 and BRCA2 mutations

Questions To Ask Your Health Care Provider

• Does my cancer test positive for a BRCA1 or BRCA2 mutation?
• Should I have genetic testing to determine whether I have an inherited mutation?
• Do you recommend neoadjuvant therapy? If so, what kind?
• Is Lynparza plus chemotherapy an option for me as standard treatment or through a clinical trial?
• What are the potential risks and benefits associated with my recommended therapy?

Open Clinical Trials

The following are studies looking at new treatments for people with metastatic TNBC.  

• NCT03606967: Testing the Addition of an Individual Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer. This study evaluates how well the combination of chemotherapy, immunotherapy and targeted therapy when used with or without a vaccine made specifically for each patient.  
• NCT04468061: Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic TNBC. This early phase study looks at the safety and effectiveness of Trodelvy with or without pembrolizumab for patients with TNBC that has spread to other parts of the body.
• NCT04020575: Using a Type of Immunotherapy Called CAR-T to Treat Metastatic Triple-Negative Breast Cancer. This study measures the safety and effectiveness of a treatment made from the patient's cancer when used for certain types of metastatic breast cancer. 
• NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent TNBC (InCITe). This trial will study how well the combination of avelumab with liposomal doxorubicin works with or without binimetinib. It also studies the combination of avelumab with sacituzumab govitecan to treat recurrent metastatic TNBC.
• NCT04837209. Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). This research study is looking to see whether the combination of dostarlimab and niraparib plus radiation therapy is safe and effective for participants with metastatic triple-negative breast cancer.
• NCT06488378: Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib. The study is looking at whether adding a new targeted therapy drug called axatilimab to treatment with the PARP inhibitor olaparib (Lynparza) will improve outcomes in people with metastatic breast cancer. 
• NCT06022029: Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas. This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas. 
• NCT06841354: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/​TroFuse-011). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Several other clinical trials for treating patients with metastatic TNBC can be found here.